A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

The disclosure provide an apparatus for producing a nuclide by using a liquid target which can perform the nuclear reaction process and can discharge the radioactive gas such as Radon within the vial. As described above, an apparatus for producing a nuclide by using a liquid target according to the present disclosure can minimize quantitative loss of a reactant by performing the nuclear reaction process using a target of a liquefied state and reusing a liquefied target on which the nuclear reaction process has not been performed, and can improve safety by enabling the radioactive gas generated to be disposed.

Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.

The present disclosure provides a complex of general formula (I), wherein M is tetravalent platinum; L is independently a neutral ligand or an anionic ligand when appearing each time; x is an integer of 1-5; P is a precursor ligand, the precursor ligand being a ligand of a tetravalent platinum ion which can be released from the complex after irradiation and converted into a functional molecule D to achieve functions such as medicine, fluorescence detection, or a functional material.

L.sub.x-M-P(I)

The invention provides for methods of delivering heparin binding epidermal growth factor (HB-EGF) to sites of intestinal injury using stem cell derived exosomes. In particular, the invention provides for methods of delivering HB-EGF loaded stem cell-derived exosomes to sites of intestinal injury and methods of protecting a subject and method of treating intestinal injury, such as necrotizing enterocolitis (NEC).

Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R.sup.5, R.sup.6, R.sup.8, R.sup.9, R.sup.11, X.sup.1, and X.sup.2 are as defined herein, as compounds for treatment and prevention of cancer and proliferative diseases and disorders.

##STR00001##

Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

##STR00001##

Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing stem cell-like memory T cells (T.sub.SCM cells). Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells.

The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.

This invention generally relates to biomarkers useful in the treatment of IL-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing IL-23 antagonists.